LC-MS/MS raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-04. Anything still debated is marked as such rather than presented as settled.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
=== Distribution === When injected, pentamidine binds to tissues and proteins in the plasma. It accumulates in the kidney, liver, lungs, pancreas, spleen, and adrenal glands. Additionally, pentamidine does not reach curative levels in the cerebrospinal fluid. It has a volume of distribution of 286–1356 liters when given intravenously and 1658–3790 liters when given intramuscularly. Inhaled pentamidine is mainly recovered from the bronchoalveolar lavage fluid of the lungs.
In that same war there was opposition from Bolivians, especially in Chuquisaca to preserve their privileges, when mentioning that the confederate project favored Peru to the detriment of Bolivia by creating 2 Peruvian states (Republic of North Peru and Republic of South Peru) that would generate a disadvantage in decisions by having the Bolivian state 1 vote of 3 (there being a general opposition to what was agreed in the Tacna Congress), Bolivians were already discontent since Santa Cruz had settled in Lima, when he was expected to rule from Bolivian Republic, so he was accused of being a Peruvianphile. Therefore, both the Bolivian opposition to Santa Cruz, as well as the Bolivian defense of the confederation against Agustín Gamarra, was nourished by anti-Peruvianism. In addition, before, during and after the War of the Pacific, discourses emerged (especially in liberal groups) with anti-militarist, anti-oligarchic, anti-caudillo and anti-Peruvian tendencies, while antimilitarism was related to anti-Peruvianism. While the "guerristas" sought to continue the war and honour the alliance with Peru, the Bolivian conservatives or pacifists sought to achieve a peace agreement with Chile as soon as possible, even if to do so they had to rant against the Peruvians. Justiniano Sotomayor Guzmán's proposal in his letters to Hilarión Daza that "Bolivia has no better friend than Chile, nor worse executioner than Peru." Later, as Paz Soldán recalls, Bolivia (already an ally of Peru since 1873) tried to dispose of Arica and Pisagua, signing treaties with Brazil in 1878.
Interestingly, this contact inhibition of locomotion among NC cells is coupled with chemical coattraction between NC cells, which allows the cells to keep in motion for efficient migration as well as to stay together, respectively, leading to collective migration. Cells are most often influenced by surrounding cells towards collective migration in development, such as polster cells which are the first to internalize at the start of gastrulation in zebrafish. Unlike neural crest cells, these cells don't exhibit contact inhibition of locomotion or coattraction, but instead migrate collectively due to E-cadherin interactions between leading cells and following cells. The following polster cells are polarized and migrate towards the animal pole of the embryo for unknown reasons, reaching their actin-rich protrusions towards the leading cells and inducing interactions between E-cadherin proteins located on following cell protrusion membranes and leading cell membranes. The interactions between E-cadherins create tension, which causes internal a-catenin (bridging extracellular E-cadherin with intracellular actin) to be stretched into an open configuration, leading to the recruitment of vinculin and eventually the orientation of actin towards the same direction of migration as the following cells. Without these E-cadherin interactions, leading cells will exhibit non-directional migration.
Sources: en.wikipedia.org
Cellular thermal shift assay (CETSA) and proteome integral solubility alteration (PISA)-based proteomics are widely used in drug discovery as label-free, mass spectrometry–compatible methods for quantifying cellular target engagement (confirming that a drug binds its intended target), deconvoluting drug targets (identifying the protein target of compounds with unknown targets), and profiling off-target interactions at the proteome scale. CETSA measures drug-induced changes in protein thermal stability in intact cells or tissues and, when combined with proteomics, enables the unbiased identification and ranking of on- and off-targets, as well as supporting phenotypic hit mechanism-of-action studies. PISA extends thermal-shift principles by integrating protein solubility changes across a temperature gradient, substantially increasing throughput and enabling multiplexed analysis of multiple compounds, concentrations, or time points. This approach facilitates high-content target deconvolution and comparative mechanism-of-action profiling, including applications in low-input or automated workflows.
Such glare can lead to serious accidents and, in the case of pilots and truck drivers, to occupational disability due to eye damage. The first accident prevention regulation was published on April 1, 1988 as BGV B2, followed on January 1, 1997 by DGUV Regulation 11 of the German Social Accident Insurance. Between January and mid-September 2010, the German Federal Aviation Office registered 229 dazzle attacks on helicopters and airplanes of German airlines nationwide. On October 18, 2017, a perpetrator of a dazzle attack on a federal police helicopter was sentenced to one year and six months in prison without parole.
=== Scientific instrumentation === HVEC represented a shift in how experimental physics acquired its tools. Before the company's founding, laboratories typically built accelerators from scratch; HVEC's mass-produced instruments made reliable high-voltage machines available to institutions without in-house engineering capacity. The result was a rapid expansion of experimental nuclear physics. At the field's peak in the mid-1970s, nearly 70 percent of published papers relied on data from HVEC accelerators. Presidential science adviser D. Allan Bromley, who worked with the first HVEC tandem at Chalk River, called the machines "superb nuclear science instruments." In a 1984 assessment, he concluded that "of all the accelerators yet devised in nuclear science I believe that a very strong case can be made that the large tandems span the greatest range and scope of physics."
Sources: en.wikipedia.org
Postcentral gyrus The gyrus in the parietal lobe that contains the primary somatosensory cortex, responsible for processing tactile information from the body. Posterior parietal cortex A region involved in integrating sensory information for spatial awareness and movement planning. Important in reaching and grasping tasks. Postganglionic neuron A neuron in the autonomic nervous system that extends from a ganglion to a target organ, influencing functions such as heart rate and digestion. Postsynaptic potential A change in membrane potential in a neuron following activation of synaptic receptors. Can be excitatory (EPSP) or inhibitory (IPSP). Prefrontal cortex The front part of the frontal lobe involved in decision-making, planning, social behavior, and personality. Highly developed in humans. Presynaptic terminal The end of an axon where neurotransmitters are released into the synaptic cleft following an action potential. Primary motor cortex A region in the frontal lobe responsible for initiating voluntary motor movements. Located in the precentral gyrus. Primary somatosensory cortex Located in the postcentral gyrus of the parietal lobe, it processes tactile and proprioceptive information from the body. Prion A misfolded protein that can cause other proteins to misfold, leading to neurodegenerative diseases such as Creutzfeldt–Jakob disease. Procedural memory A type of long-term memory for performing tasks and skills (e.g., riding a bike), often associated with the basal ganglia and cerebellum.
== Social issues == To address social issues arising from the casinos, such as problem gambling, the National Council on Problem Gambling (NCPG) was created in 2005. In 2017, controversies surrounding association football club operations, which had been known to host slot machine rooms to fund their sporting activities for more than the past two decades prior to 2014, arose that called for additional safeguards to prevent gambling addicts from frequenting such places from Members of Parliament (MP) who had also raised concerns over current regulations following investigation of Tiong Bahru Football Club, an semi-professional football club in the National Football League, the second tier of national football league system. generated approximately 10 times more revenue from their 29-slot machine operations than what the Tampines Rovers, a professional football club in the S.League, had reportedly earned in their 2013/2014 financial year. Other noted cases included Sinchi Football Club, which continued to operate a clubhouse with six slot machines despite having not played in any S.League football game since 2005 and prompted a need to ensure profits from slot operations were going towards funding a club's core purpose--their football activities.
== Background == Glutathione plays a central role in cellular redox balance, detoxification, and immune regulation. Its synthesis depends on the availability of several amino acid substrates, of which cysteine is typically the rate-limiting precursor under physiological conditions. Free L-cysteine is chemically unstable and readily oxidized in the gastrointestinal tract, which can limit its effectiveness when administered directly as a supplement. For this reason, a variety of cysteine-delivery strategies have been explored, including N-acetylcysteine (NAC) and other cysteine prodrugs. D-Ribose-L-cysteine was developed as an alternative cysteine-delivery compound intended to improve cysteine stability and intracellular availability for glutathione synthesis.
=== Serotonin 5-HT2A receptor antagonists === Serotonin 5-HT2A receptor antagonists such as ritanserin, ketanserin, eplivanserin, volinanserin, nelotanserin, and pimavanserin have been studied and developed to improve sleep. They do not improve sleep onset, but have been found to increase slow wave sleep (deep sleep) and reduce nighttime awakenings. Conversely, improvement in subjective sleep ratings have been more mixed. Ultimately no selective serotonin 5-HT2A receptor antagonists have been approved for treatment of insomnia. The only selective serotonin 5-HT2A receptor antagonist to be approved for any indication is pimavanserin for treatment of Parkinson's disease psychosis. Besides selective serotonin 5-HT2A receptor antagonists however, many non-selective agents used as hypnotics show serotonin 5-HT2A receptor antagonism, for instance antidepressants like trazodone, mirtazapine, and amitriptyline, antipsychotics like quetiapine and olanzapine, and antihistamines like hydroxyzine and cyproheptadine.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.